UV-B Phototherapy of Psoriasis

Boer, Jurr; Schothorst, A.A.; Suurmond, D.

doi:10.1159/000250373

Cited by 37 publications

(15 citation statements)

References 10 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In mice, artificially administered UVB induces skin tumors (Wulf et al, 1994). Although UVB is widely used as a treatment for moderate-to-severe psoriasis and other skin conditions, the carcinogenicity of therapeutic UVB in humans is not well quantified (Boer et al, 1980;Anderson et al, 1984). Based on the emission spectra of broadband UVB lamps and the sun, Nachtwey and Rundel (1981) estimated that broadband UVB might be twice as carcinogenic per minimal erythemal dose as the sun.…”

mentioning

confidence: 99%

High Levels of Ultraviolet B Exposure Increase the Risk of Non-Melanoma Skin Cancer in Psoralen and Ultraviolet A-Treated Patients

Lim

Stern

2005

Journal of Investigative Dermatology

133

View full text Add to dashboard Cite

Sunlight and psoralen and ultraviolet A (PUVA) are risk factors for the development of squamous cell carcinoma (SCC) and, to a lesser extent, basal cell carcinoma (BCC). Ultraviolet B (UVB) therapy, used for the treatment of psoriasis, might also increase the risk of these tumors. We studied the relation of skin cancer incidence to UVB use among 1380 adult subjects enrolled in a long-term safety trial of PUVA therapy. We used negative binomial regression models to quantify the association between UVB and the development of non-melanoma skin cancer (NMSC), controlling for known confounders. High UVB exposure (> or =300 treatments vs <300 treatments) was associated with a modest but significant increase in SCC (adjusted incidence rate ratio (IRR)=1.37, 95% confidence interval (CI)=1.03-1.83) and BCC (adjusted IRR=1.45, 95% CI=1.07-1.96) risk. Among patients with <100 PUVA treatments, high UVB exposure was significantly associated with the development of SCC (adjusted IRR=2.75, 95% CI=1.11-6.84) and BCC (adjusted IRR=3.00, 95% CI=1.30-6.91) on body sites typically exposed to UVB therapy but not on chronically sun-exposed sites typically covered during therapy. For adults with high UVB exposure levels, UVB confers a modest increase in NMSC risk, much less than that observed with PUVA. Therefore, UVB remains a relatively low-risk treatment for psoriasis.

show abstract

mentioning

confidence: 99%

High Levels of Ultraviolet B Exposure Increase the Risk of Non-Melanoma Skin Cancer in Psoralen and Ultraviolet A-Treated Patients

Lim

Stern

2005

Journal of Investigative Dermatology

133

View full text Add to dashboard Cite

show abstract

“…Remission times were prolonged using maintenance therapy. [26][27][28] The advent of NB-UVB lamps improved the use of UVB therapy in psoriasis and is widely considered to be preferable to BB-UVB therapy. NB-UVB use was initially popularized in the United Kingdom and Europe in the mid-1980s, and became available in the United States approximately one decade later.…”

Section: Efficacymentioning

confidence: 99%

Guidelines of care for the management of psoriasis and psoriatic arthritis

Menter

Korman

Elmets

et al. 2010

Journal of the American Academy of Dermatology

316

View full text Add to dashboard Cite

“…In another trial, 90% of psoriatic patients experienced complete disease clearance with BB-UVB combined with petrolatum three times weekly for 3-13 weeks (12). Remission times have also been prolonged when using BB-UVB for maintenance therapy (13). With the advent of NB-UVB bulbs, several small clinical studies have demonstrated increased efficacy and more rapid clearance of psoriatic plaques with NB-UVB compared to BB-UVB phototherapy (14)(15)(16)(17).…”

Section: Discussionmentioning

confidence: 99%

Broadband UVB revisited: Is the narrowband UVB fad limiting our therapeutic options?

Pugashetti

Lim

Koo

2009

Journal of Dermatological Treatment

View full text Add to dashboard Cite

Broadband ultraviolet B (BB-UVB) phototherapy has demonstrated efficacy in the treatment of cutaneous disorders including psoriasis, atopic dermatitis, uremic pruritus and idiopathic pruritus. In the last decade, there has been a rapidly escalating process of replacing BB-UVB phototherapy units with narrowband ultraviolet B (NB-UVB) equipment, as studies have demonstrated that NB-UVB (ranging from 311 mm to 312 nm) is more efficacious in the treatment of psoriasis. Nevertheless, it is important to recognize the efficacy of BB-UVB phototherapy in the treatment of uremic pruritus, idiopathic pruritus, eosinophilic folliculitis and other inflammatory pruritic conditions. Furthermore, as highlighted in this report, there is a small but significant proportion of psoriasis and atopic dermatitis patients who do not tolerate NB-UVB but demonstrate an excellent clinical response to BB-UVB. It is critical for dermatologists to recognize the role of BB-UVB as a complement to NB-UVB phototherapy for patients who cannot tolerate or experience an inadequate therapeutic response from NB-UVB.

show abstract

UV-B Phototherapy of Psoriasis

Cited by 37 publications

References 10 publications

High Levels of Ultraviolet B Exposure Increase the Risk of Non-Melanoma Skin Cancer in Psoralen and Ultraviolet A-Treated Patients

High Levels of Ultraviolet B Exposure Increase the Risk of Non-Melanoma Skin Cancer in Psoralen and Ultraviolet A-Treated Patients

Guidelines of care for the management of psoriasis and psoriatic arthritis

Broadband UVB revisited: Is the narrowband UVB fad limiting our therapeutic options?

Contact Info

Product

Resources

About